Eleanor Lisbon
Dr. Eleanor Lisbon, MD, MPH, brings over 18 years of clinical drug development experience (Phase 1-Phase 3).
Prior to Marrow, Dr. Lisbon served as an Executive Medical Director at Pfizer with deep expertise in first-in-human (FIH), Phase 1 clinical development and safety review, specializing in small molecules and hemoglobinopathies, including SCD. Previously, she was an Associate Professor of Family Medicine at the University of Kansas Medical Center (KUMC) for 10 years. Dr. Lisbon has proficiency in clinical pharmacology, exposure–response, modeling and simulation, dose escalation, with a proven track record of accelerating early-stage drug pipelines and advancing patient-centered clinical development.
Dr. Lisbon earned her BS and MD from Howard University, and earned her MPH from the University of Kansas. She also holds a certificate in executive education from Harvard Kennedy School, Boston, Massachusetts.